骨髓纤维化患者血栓形成、大出血与死亡率:一项基于人群的1079例匹配研究
这项基于瑞典多登记库的全国性人群匹配研究纳入1079例骨髓纤维化(MF)患者及5395例匹配对照,评估大出血、血栓事件及全因死亡率。MF患者大出血、动脉及静脉事件发生率分别为每100人年2.55、2.59和1.06次;与对照相比,出血、动脉事件、静脉事件及死亡风险均升高。接受JAK抑制剂治疗者的出血与血栓事件发生率高于未接受症状导向治疗或羟基脲治疗者。
要点
- MF患者大出血、动脉事件、静脉事件及死亡风险均高于匹配对照人群。
- JAK抑制剂治疗者大出血、动脉及静脉事件发生率高于未治疗或羟基脲治疗者。
- 既往动静脉事件、高龄、JAK抑制剂或低分子肝素使用等为独立风险因素。
核心结论
- 骨髓纤维化患者血栓栓塞事件及大出血发生率高于其他骨髓增殖性肿瘤,且血栓栓塞并发症与大出血在不同治疗组间呈现差异。
研究设计与样本
- 全国性人群匹配研究,利用瑞典多个医疗登记库纳入1079例骨髓纤维化患者及5395例匹配对照。
主要发现
- MF患者大出血、动脉事件及静脉事件发生率分别为每100人年2.55、2.59和1.06次。
- 与对照相比,出血风险比为3.78(95%CI 2.98-4.79;P<.001),动脉事件风险比为1.73(95%CI 1.40-2.12;P<.001),静脉事件风险比为2.75(95%CI 1.93-3.90;P<.001),死亡风险比为3.92(95%CI 3.50-4.40;P<.001)。
- 接受JAK抑制剂治疗者大出血、动脉事件及静脉事件发生率分别为5.33、4.67和1.56,高于未接受持续症状导向治疗者(分别为2.32、2.15和0.79)及羟基脲治疗者(分别为2.05、2.35和1.27)。
- JAK抑制剂或低分子肝素使用、既往动脉或静脉事件及高龄被确定为新的动脉或静脉事件的独立风险因素。
- 既往静脉事件、诊断时较高白细胞计数及持续JAK抑制剂治疗与 major bleeding 风险增加相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bleeding and thrombotic events are known complications in myeloproliferative neoplasms (MPNs), but few studies have exclusively focused on patients with myelofibrosis (MF). In this nationwide population-based study, we assessed the frequency of major bleeding, thrombotic events, and all-cause mortality in 1079 patients diagnosed with MF and 5395 matched controls using multiple Swedish health care registers. Major bleeding, arterial, and venous events were seen at a rate of 2.55, 2.59, and 1.06 events per 100 years, respectively, in patients with MF. Compared to controls, the rates of bleedings, arterial events, venous events, and mortality were increased, with hazard ratios of 3.78 (95% confidence interval [CI], 2.98-4.79; P < .001), 1.73 (95% CI, 1.40-2.12; P < .001), 2.75 (95% CI, 1.93-3.90; P < .001), and 3.92 (95% CI, 3.50-4.40; P < .001), respectively. Patients treated with JAK inhibitors (JAKis) had higher rates of major bleeding (5.33), arterial events (4.67), and venous events (1.56) than patients with no ongoing symptom-directed therapy (rates, 2.32, 2.15, and 0.79) or hydroxyurea (rates, 2.05, 2.35, and 1.27, respectively). The use of JAKis or low-molecular-weight heparin, previous arterial or venous events, and older age were identified as independent risk factors for new arterial or venous events. A previous venous event, higher leukocyte count at diagnosis, and ongoing JAKi treatment were associated with an increased risk of major bleeding. This study shows that patients with MF have higher rates of thromboembolic events and major bleeding than described in other MPNs, and thromboembolic complications and major bleeding diverge in the different treatment groups.
引用
- Enblom Larsson A, Renlund H, Andréasson B, et al. Thrombosis, major bleeding, and mortality in 1079 patients with myelofibrosis: a matched population-based study. Blood Adv. 2025. PMID: 40117492. doi:10.1182/bloodadvances.2025016247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。